Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood BlindnessGlobeNewsWire · 3 days ago
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaGlobeNewsWire · Oct 16, 2026
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026GlobeNewsWire · Oct 15, 2026
Opus Genetics to Present at the Chardan Annual Healthcare ConferenceGlobeNewsWire · Oct 13, 2026
Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Recommendation of “Moderate Buy” from BrokeragesDefense World · Oct 1, 2026
Squarepoint Ops LLC Takes $1.36 Million Position in Opus Genetics, Inc. $IRDDefense World · Sep 17, 2026Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.16 | -$0.14 | Beat |
| May 12, 2026 | -$0.16 | -$0.75 | Miss |
| Mar 10, 2026 | -$0.11 | -$0.14 | Miss |
| Nov 12, 2025 | -$0.14 | -$0.25 | Miss |
| Aug 13, 2025 | -$0.25 | -$0.12 | Beat |
| May 15, 2025 | -$0.34 | -$0.24 | Beat |